| | | | | | | | | | | | | | | | | | | | | | | 截 | 至 | | 六 月 | | 三 | 十 日 | 止 | | 六 | 個 | | 月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | | | | | | | | | | | | | 二 | | 零 | 二 | 五 | 年 | 二 | 零 | | 二 | 四 | | 年 | | | | | | | | | | | | | | | | | | | | | | | | 附 | 註 | | | 港 | 幣 | 千 | 元 | | 港 | | 幣 | 千 | | 元 | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 China Golden Classic Group Limited 中國金典集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：8281） 由 於 購 股 權 計 劃 項 下 未 授 出 任 何 購 股 權，因 此 概 無 已 授 出 購 股 權 的 特 定 歸 屬 期。 上 述 補 充 資 料 並 無 影 響 於 二 零 二 四 年 年 報 所 載 之 其 他 資 料。除 上 文 所 披 露 者 外，二 零 二 四 年 年 報 所 載 一 切 其 他 資 料 均 維 持 不 變。 承董事會命 中國金典集團有限公司 除 於 二 零 二 四 年 年 報 所 披 露 之 資 料 外，本 公 司 謹 此 擬 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 購 股 權 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本文檔全部或任何部份內容而産生或因倚賴該等內容而引致 的任何損失承擔任何責任。 中國上海─ 2025 年 8 月 7 日─ 國際主要半導體代工製造商中芯國際集成電路製造有限公司(香港聯交所 股份代號：00981；上交所科創板證券代碼：688981)(「中芯國際」、「本公司」或「我們」)於今日公佈 截至 2025 年 6 月 30 日止三個月的綜合經營業績。 *僅供識別 -1- 2025 年第二季的銷售收入為 2,209.1 百萬美元，2025 年第一季的銷售收入為 2,247.2 百萬美元， 2024 年第二季的銷售收入為 1,901.3 百萬美元。 2025 年第二季毛利為 449.8 百萬美元，2025 年第一季毛利為 505.9 百萬美元，2024 年第二季毛 利為 265.1 百萬美元。 2025 年第二季毛利率為 20.4%，2025 年第一季毛利率為 22.5%，2024 年第二季毛利率為 13.9%。 以下聲明爲前瞻性陳述，基於目前的預期並涵蓋風險和不確定性。 SEM ...

目錄 2 公司資料 4 管理層討論及分析 9 其他資料 21 簡明綜合損益及其他全面收益表 23 簡明綜合財務狀況表 25 簡明綜合權益變動表 26 簡明綜合現金流量表 28 簡明綜合財務報表附註 公司資料 董事會 執行董事 司徒志仁先生 （主席） TAN William先生 （行政總裁（「行政總裁」）） 李耀明先生 獨立非執行董事 施德華先生 ANDERSEN Dee Allen先生 KESEBI Lale女士 劉可瑞先生 審核委員會 提名委員會 司徒志仁先生 （主席） 施德華先生 ANDERSEN Dee Allen先生 KESEBI Lale女士 劉可瑞先生 公司秘書 李耀明先生 註冊辦事處 Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands 施德華先生 （主席） ANDERSEN Dee Allen先生 KESEBI Lale女士 劉可瑞先生 薪酬委員會 ANDERSEN Dee Allen先生 （主席） 施德華先生 司徒志仁先生 KESEBI Lale女士 劉可瑞先生 香港主要營業地點 香港 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：3999） 截至二零二五年六月三十日止六個月中期業績公佈 大成食品（亞洲）有限公司（「本公司」）董事會（「董事會」）謹此公佈本公司及其附屬公司（以下合稱「本集 團」）截至二零二五年六月三十日止六個月的未經會計師審核綜合業績： 財務摘要 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | 二零二五年 | 二零二四年 | 增減百分比 | | | （未經審核） | （未經審核） | | | 經營收入（人民幣千元） | 2,909,838 | 2,794,444 | 4.1 | | 毛利（人民幣千元） | 305,500 | 362,471 | -15.7 | | 毛利率(%) | 10.5 | 13.0 | | | 本公司股東應佔（虧損）╱溢利（人民幣千元） | (35,070) | 31,575 | -211 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公布的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示 概不就因本公布全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 * 截至2025年6月30日止六個月 的中期業績公布 太平洋航運集團有限公司（「太平洋航運」或「本公司」）董事會（「董事會」）欣然公布本公司及其附屬公司（統稱「本集團」）截至2025年6月30 日止六個月的未經審核簡明綜合業績如下： 業務摘要 在市況疲弱下展現財務韌性 業務表現 | | 截至6月30日止六個月 | | | --- | --- | --- | | 百萬美元 | 2025年 | 2024年 | | 營業額 | 1,018.7 | 1,281.5 | | 稅息折舊及攤銷前溢利 # | 121.5 | 157.9 | | 基本溢利 | 21.9 | 43.9 | | 股東應佔溢利 | 25.6 | 57.6 | | （港仙） 每股基本盈利 | 3.9 | 8.7 | | 每股中期股息 （港仙） | 1.6 | 4.1 | 稅息折舊及攤銷前溢利乃按毛利減間接一般及行政管理開支計算，不包括折 舊及攤銷、 ...

[Corporate Information](index=3&type=section&id=Corporate%20Information) This section provides basic corporate information for Asia Cement (China) Holdings Corporation, including its board and key personnel [Corporate Information](index=3&type=section&id=Corporate%20Information) This chapter provides basic corporate information for Asia Cement (China) Holdings Corporation, including its key personnel and professional advisors - The company's Chairman is Mr Hsu, Hsu-Tung, and the Chief Executive Officer is Mr Chang, Chen-Kuen[8](index=8&type=chunk) - The company's auditor is Deloitte Touche Tohmatsu[12](index=12&type=chunk) [Financial Highlights](index=6&type=section&id=Financial%20Highlights) The company achieved a turnaround to profitability for the six months ended June 30, 2025, despite a revenue decline [Financial Highlights](index=6&type=section&id=Financial%20Highlights) The company turned from a loss to a profit in H1 2025, driven by a significant gross margin improvement despite lower revenue Semi-Annual Performance Overview | Indicator | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | RMB 2,496 million | RMB 2,689 million | -7.2% | | Gross Profit | RMB 411 million | RMB 133 million | +209% | | Profit (Loss) for the period | RMB 117 million | (RMB 411) million | Turnaround | | Profit (Loss) attributable to owners | RMB 114 million | (RMB 405) million | Turnaround | | Gross Profit Margin | 16% | 5% | +11 p.p. | | Basic Earnings (Loss) Per Share | RMB 0.073 | (RMB 0.258) | Turnaround | Key Financial Ratios | Indicator | June 30, 2025 | Dec 31, 2024 | Change | | :--- | :--- | :--- | :--- | | Current Ratio | 3.59 | 4.77 | Decreased | | Quick Ratio | 3.35 | 4.53 | Decreased | | Gearing Ratio | 0.13 | 0.14 | Slightly Decreased | [Condensed Consolidated Financial Statements](index=7&type=section&id=Condensed%20Consolidated%20Financial%20Statements) This section presents the Group's interim financial statements, including income, financial position, equity, and cash flows [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=7&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) The Group's profit for the period turned positive to RMB 117 million, driven by a significant reduction in cost of sales Core Data from the H1 2025 Income Statement | Item | H1 2025 (RMB'000) | H1 2024 (RMB'000) | | :--- | :--- | :--- | | Revenue | 2,496,296 | 2,689,407 | | Cost of sales | (2,085,056) | (2,556,427) | | **Gross Profit** | **411,240** | **132,980** | | Profit (loss) before tax | 169,915 | (223,643) | | **Profit (loss) for the period** | **116,972** | **(411,205)** | | Profit (loss) attributable to owners | 114,418 | (404,853) | | Basic earnings (loss) per share | RMB 0.073 | (RMB 0.258) | [Condensed Consolidated Statement of Financial Position](index=8&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) The Group's total assets remained stable at RMB 19.63 billion, with a notable shift from cash to time deposits Key Balance Sheet Items | Item | June 30, 2025 (RMB'000) | Dec 31, 2024 (RMB'000) | | :--- | :--- | :--- | | **Total Assets** | **19,628,972** | **19,677,550** | | Non-current Assets | 11,686,695 | 8,891,959 | | Current Assets | 7,942,277 | 10,785,591 | | **Total Liabilities** | **2,632,005** | **2,797,555** | | Current Liabilities | 2,212,351 | 2,263,184 | | Non-current Liabilities | 419,654 | 534,371 | | **Net Assets** | **16,996,967** | **16,879,995** | | **Total Equity** | **16,996,967** | **16,879,995** | - Bank balances and cash decreased from RMB 8.88 billion to RMB 1.56 billion, while time deposits with original maturity over three months increased by **RMB 7.50 billion**, indicating a shift in cash management strategy[17](index=17&type=chunk) [Condensed Consolidated Statement of Changes in Equity](index=10&type=section&id=Condensed%20Consolidated%20Statement%20of%20Changes%20in%20Equity) Total equity increased to RMB 17.00 billion, primarily due to the profit generated during the period - Equity attributable to owners of the Company increased from RMB 16.52 billion at the beginning of 2025 to **RMB 16.63 billion**, mainly driven by the profit of RMB 114 million for the period[20](index=20&type=chunk) [Condensed Consolidated Statement of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) Net cash from operating activities increased significantly, while cash used in investing activities decreased sharply Cash Flow Summary | Item | H1 2025 (RMB'000) | H1 2024 (RMB'000) | | :--- | :--- | :--- | | Net cash from operating activities | 319,885 | 145,761 | | Net cash used in investing activities | (29,523) | (2,756,723) | | Net cash used in financing activities | (20,764) | (833,231) | | Net increase (decrease) in cash | 269,598 | (3,444,193) | | Cash at beginning of period | 1,294,559 | 5,718,017 | | **Cash at end of period** | **1,564,157** | **2,273,824** | [Notes to the Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue composition, and segment information, with no interim dividend declared [3. Revenue](index=13&type=section&id=3.%20Revenue) Total revenue in H1 2025 was RMB 2.50 billion, with cement products accounting for 97.7% of the total Revenue Breakdown | Product Category | H1 2025 Revenue (RMB'000) | H1 2024 Revenue (RMB'000) | | :--- | :--- | :--- | | Sales of cement products and related products | 2,438,060 | 2,621,481 | | Sales of concrete | 58,236 | 67,926 | | **Total** | **2,496,296** | **2,689,407** | [4. Segment Information](index=13&type=section&id=4.%20Segment%20Information) The cement business segment was the key driver of the Group's turnaround, while the concrete business remained loss-making Segment Results | Business Segment | H1 2025 Segment Results (RMB'000) | H1 2024 Segment Results (RMB'000) | | :--- | :--- | :--- | | Cement business | 221,884 | (203,521) | | Concrete business | (17,089) | (14,924) | | **Total** | **204,795** | **(218,445)** | [9. Dividends](index=17&type=section&id=9.%20Dividends) The Board of Directors did not recommend an interim dividend for the six months ended June 30, 2025 - The Board does not recommend the payment of an interim dividend for 2025 (H1 2024: Nil)[48](index=48&type=chunk)[49](index=49&type=chunk) [Management Discussion and Analysis](index=24&type=section&id=Management%20Discussion%20and%20Analysis) This section reviews the Group's business performance, financial position, and future outlook amid challenging market conditions [Business and Financial Review](index=24&type=section&id=Business%20and%20Financial%20Review) The Group achieved a turnaround despite a sluggish market by improving cement selling prices and reducing coal costs - Market Environment: In H1 2025, real estate development investment **decreased by 11.2% year-on-year**, leading to continued weak demand in the national cement market, with national cement output falling by 4.3%[75](index=75&type=chunk)[76](index=76&type=chunk) - Performance Attribution: Despite lower sales volume, the company improved its average cement selling price through industry coordination and benefited from lower coal costs, boosting its **gross margin from 5% to 16%** and achieving a turnaround[77](index=77&type=chunk)[78](index=78&type=chunk)[84](index=84&type=chunk) Sales Analysis by Region | Region | H1 2025 Revenue (RMB'000) | H1 2024 Revenue (RMB'000) | | :--- | :--- | :--- | | Southeast region | 1,406,488 | 1,604,298 | | Central China region | 368,955 | 282,491 | | Southwest region | 720,853 | 802,618 | | **Total** | **2,496,296** | **2,689,407** | [Financial Resources and Liquidity](index=28&type=section&id=Financial%20Resources%20and%20Liquidity) The Group maintained a healthy financial position with a low gearing ratio of 13% as of June 30, 2025 - As of June 30, 2025, the Group held **RMB 1.56 billion in cash and cash equivalents**, along with RMB 7.50 billion in time deposits with original maturity over three months[95](index=95&type=chunk)[98](index=98&type=chunk) - The Group's gearing ratio (total liabilities to total assets) **decreased from 14% at the end of 2024 to 13%** as of June 30, 2025[96](index=96&type=chunk)[98](index=98&type=chunk) [Prospects](index=31&type=section&id=Prospects) Management anticipates continued market challenges but expects performance to improve through supply-side discipline and cost control - Market Expectation: The downward trend in overall cement demand is expected to continue, with industry profitability dependent on **supply-side improvements and corporate self-discipline**[121](index=121&type=chunk)[123](index=123&type=chunk) - Industry Policy: The China Cement Association's push to curb excessive competition by requiring production according to filed capacity is expected to **reduce supply and rationalize the market**[121](index=121&type=chunk)[123](index=123&type=chunk) - Company Strategy: The Group will adhere to its high-efficiency and high-quality strategy, continue cost reduction efforts, and strengthen industry communication, expecting **further performance improvement in H2**[122](index=122&type=chunk)[123](index=123&type=chunk) [Other Information](index=32&type=section&id=Other%20Information) This section covers shareholder interests and corporate governance practices during the reporting period [Disclosure of Interests](index=32&type=section&id=Disclosure%20of%20Interests) This section discloses the interests of directors and substantial shareholders, with Asia Cement being the controlling shareholder Substantial Shareholders' Interests | Name of shareholder | Capacity | Number of shares held | Approximate percentage of issued share capital | | :--- | :--- | :--- | :--- | | Asia Cement | Beneficial owner & controlled corporation | 1,144,862,000 | 73.07% | | Far Eastern New Century Corporation | Beneficial owner & controlled corporation | 1,144,862,000 | 73.07% | [Corporate Governance](index=35&type=section&id=Corporate%20Governance) The company complied with the Corporate Governance Code and its Audit Committee reviewed the interim financial statements - The company has complied with all provisions of the Corporate Governance Code for the six months ended June 30, 2025[135](index=135&type=chunk)[141](index=141&type=chunk) - The Audit Committee has reviewed the interim financial statements and considers their preparation to be in compliance with accounting standards and adequately disclosed[137](index=137&type=chunk)[142](index=142&type=chunk)

HUA HONG SEMICONDUCTOR LIMITED 華 虹 半 導 體 有 限 公 司 01347 — 2025 8 7 — 01347 688347) (" ") 1 ◼ 5.661 18.3% 4.6% ◼ 10.9% 0.4 1.7 ◼ 800 19.2% 112.1% 12 2 https://edge.media-server.com/mmc/p/pemdk6h6 ◼ 6.2 6.4 ◼ 10% 12% 5.66 10.9% PIN https://register-conf.media-server.com/register/BI1686ec5f75fa43e1a37307d2e98221ed PIN PIN 2 12 https://www.huahonggrace.com/c/ir_calendar.php A : 688347 01347 8 + 12 IC + Power Discrete / 8 + 12 8 12 12 www.huahonggrace.com 3 2025 8 7 17:00 / 05:00 https://www.huahonggrace.com/c/ir ...

[Company Information](index=4&type=section&id=%E5%85%AC%E5%8F%B8%E8%B3%87%E6%96%99) This section provides fundamental information about the company [Financial Highlights](index=5&type=section&id=2025%E5%B9%B4%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) For H1 2025, the Group's total revenue decreased by 16.7% to S$3.7 million, with gross profit down 17.5% to S$2.5 million, primarily due to market competition, macroeconomic pressures, and regulatory changes. Increased investment in the Philippine education business led to a net loss of S$1.2 million, significantly higher than S$0.15 million in the prior year, with no interim dividend declared 2025 H1 Key Financial Indicators | Indicator | 2025 H1 (S$) | 2024 H1 (S$) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Revenue | 3.7 million | 4.5 million | -16.7% | | Gross Profit | 2.5 million | 3.1 million | -17.5% | | Net Loss After Tax | 1.20 million | 0.15 million | +700% | - The **16.7% decrease in medical business sales** is primarily attributed to increased market competition, macroeconomic pressures, and regulatory developments[9](index=9&type=chunk)[11](index=11&type=chunk) - **Increased market competition**: New entrants and existing providers expanding their reach have diverted patient groups - **Macroeconomic pressures**: Rising cost of living and economic uncertainty have made patients more price-sensitive, leading to delayed non-essential treatments or seeking more economical options - **Regulatory developments**: New healthcare regulations have increased compliance costs and operational burdens - The expansion of net loss is mainly due to increased investment in the Philippine education business, resulting in approximately **S$0.49 million increase in other operating expenses**[10](index=10&type=chunk) - The Board has resolved not to declare any dividend for the period, consistent with the prior year[14](index=14&type=chunk) [Unaudited Condensed Consolidated Financial Statements](index=7&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8) This section presents the Group's unaudited financial statements for the six months ended June 30, 2025, including the statements of profit or loss, financial position, changes in equity, and cash flows, along with relevant accounting policies and notes. The statements indicate a decline in revenue, expanded losses, and increased cash outflows, yet maintain a stable asset and liability structure with no external borrowings [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=7&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) For the six months ended June 30, 2025, Group revenue was S$3.73 million, a 16.7% year-on-year decrease. Due to reduced revenue and other operating expenses increasing from S$0.99 million to S$1.48 million, the net loss for the period significantly widened from S$0.149 million in the prior year to S$1.217 million, resulting in a basic loss per share of 0.20 Singapore cents Key Items from Consolidated Statement of Profit or Loss (For the six months ended June 30) | Item | 2025 (S$) | 2024 (S$) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Revenue | 3,734,532 | 4,481,738 | -16.7% | | Other Operating Expenses | (1,482,966) | (989,395) | +49.9% | | Net Loss for the Period | (1,216,725) | (149,149) | +715.8% | | Basic Loss Per Share (Singapore cents) | (0.20) | (0.03) | +566.7% | [Consolidated Statement of Financial Position](index=8&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E7%8B%80%E6%B3%81%E8%A1%A8) As of June 30, 2025, the Group's total assets were S$13.65 million, a slight decrease from S$14.48 million at the end of 2024. Total liabilities increased to S$2.34 million, mainly due to higher lease liabilities. Net assets (equity) decreased to S$11.31 million, while cash and cash equivalents remained strong at S$9.61 million, indicating robust liquidity Key Items from Consolidated Statement of Financial Position | Item | June 30, 2025 (S$) | December 31, 2024 (S$) | Period Change | | :--- | :--- | :--- | :--- | | Total Assets | 13,649,957 | 14,478,888 | -5.7% | | Total Liabilities | 2,342,840 | 1,928,113 | +21.5% | | Net Assets | 11,307,117 | 12,550,775 | -9.9% | | Cash and Cash Equivalents | 9,613,162 | 11,367,752 | -15.4% | [Consolidated Statement of Changes in Equity](index=10&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%AC%8A%E7%9B%8A%E8%AE%8A%E5%8B%95%E8%A1%A8) For the six months ended June 30, 2025, total equity attributable to equity holders decreased from S$12.55 million at the beginning of the period to S$11.31 million at the end, primarily due to a total comprehensive loss of S$1.24 million recorded during the period - Total equity decreased from **S$12,550,775** at the beginning of the period to **S$11,307,117** at the end, primarily due to a **total comprehensive loss of S$1,243,658** for the current period[20](index=20&type=chunk) [Consolidated Statement of Cash Flows](index=11&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E7%8F%BE%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In H1 2025, the Group's net decrease in cash and cash equivalents was S$1.75 million. Operating activities shifted from a net cash inflow in the prior year to a net outflow of S$0.82 million, reflecting deteriorating business performance. Investing and financing activities recorded net cash outflows of S$0.64 million and S$0.29 million, respectively Cash Flow Statement Summary (For the six months ended June 30) | Item | 2025 (S$) | 2024 (S$) | | :--- | :--- | :--- | | Net Cash from Operating Activities | (823,484) | 448,743 | | Net Cash from Investing Activities | (637,220) | (1,971,837) | | Net Cash from Financing Activities | (293,886) | (265,120) | | Net Decrease in Cash and Cash Equivalents | (1,754,590) | (1,788,214) | [Notes to the Financial Statements](index=12&type=section&id=%E6%9C%AA%E7%B6%93%E5%AF%A9%E6%A0%B8%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8%E9%99%84%E8%A8%BB) The notes detail the basis of preparation, accounting policies, and specifics of various financial statement items. The Group's main businesses include operating medical diagnostic centers and providing healthcare-related education in Singapore. Revenue is disaggregated by service type, showing a year-on-year decline across all medical services (treatment, medical examination, consultation). The notes also disclose changes in non-current items such as property, plant and equipment, right-of-use assets, and lease liabilities. As of the reporting period end, the Group had no significant contingent liabilities - The Group primarily engages in two main businesses: (i) operating medical diagnostic centers and providing management consultancy services in Singapore; and (ii) healthcare-related education business[22](index=22&type=chunk) Revenue by Type of Medical Services (For the six months ended June 30) | Type of Medical Services | 2025 (S$) | 2024 (S$) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Treatment Services | 2,238,278 | 2,763,858 | -19.0% | | Medical Examination Services | 964,449 | 1,074,389 | -10.2% | | Consultation Services | 531,805 | 643,491 | -17.3% | | **Total** | **3,734,532** | **4,481,738** | **-16.7%** | - As of June 30, 2025, the Group had no significant contingent liabilities or guarantees[71](index=71&type=chunk) [Management Discussion and Analysis](index=28&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E5%8F%8A%E5%88%86%E6%9E%90) Management attributes the 16.7% revenue decline to intense market competition and macroeconomic pressures. To address challenges, the company is actively pursuing strategic initiatives, including a planned investment in Long Valley Bio's dendritic cell (DC) vaccine technology to expand into Southeast Asia and Greater China, and positioning healthcare education as a new strategic growth pillar. Despite short-term investment-driven losses, the company maintains a robust financial position with no bank borrowings and S$9.6 million in cash. IPO proceeds have been fully utilized, with remaining placement proceeds earmarked for future acquisitions [Business Review and Outlook](index=28&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7%E8%88%87%E5%B1%95%E6%9C%9B) The Group operates a network of medical clinics in Singapore under the "DTAP" brand. Facing a challenging market, the company is pursuing long-term value through strategic expansion and innovation. A key initiative involves an intended investment agreement with Long Valley Bio for its approved proprietary dendritic cell (DC) vaccine technology to treat malignant tumors, aiming to deepen its Southeast Asian presence and explore opportunities in Greater China. Additionally, healthcare education is a strategic development pillar to cultivate new sustainable revenue streams, with investments in technologies like telemedicine to enhance service quality - The company plans to invest in Long Valley Bio, leveraging its approved proprietary dendritic cell (DC) vaccine technology, to deepen its presence in Southeast Asia and explore high-growth opportunities in Greater China[74](index=74&type=chunk)[75](index=75&type=chunk) - The company views healthcare education as a strategic focus area and a new sustainable revenue source, having launched a series of training programs[76](index=76&type=chunk) - To address intense competition, the company prioritizes enhancing service quality, integrating technology (such as telemedicine platforms and electronic medical records), and diversifying clinical services[76](index=76&type=chunk) [Financial Review](index=30&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%A7) In H1 2025, revenue decreased by 16.7% year-on-year to S$3.7 million, and gross profit fell to S$2.5 million, though the gross profit margin remained relatively stable. Net loss expanded from S$0.1 million in the prior year to S$1.2 million, primarily due to lower revenue, a 3.9% increase in employee benefits expenses, and a significant rise in other operating expenses driven by investments in education business expansion and foreign exchange losses Financial Performance Review (For the six months ended June 30) | Indicator | 2025 H1 (S$) | 2024 H1 (S$) | Change | | :--- | :--- | :--- | :--- | | Revenue | approx 3.7 million | approx 4.4 million | -16.7% | | Gross Profit | approx 2.5 million | approx 3.1 million | -19.4% | | Employee Benefits Expenses | approx 2.05 million | approx 1.98 million | +3.9% | | Loss for the Period | approx 1.2 million | approx 0.1 million | Loss widened | - The increase in other operating expenses is primarily due to ongoing investments in education business expansion and foreign exchange losses related to foreign currency denominated balances[84](index=84&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=%E6%B5%81%E5%8B%95%E6%80%A7%E8%88%87%E8%B3%87%E6%9C%AC%E8%B3%87%E6%BA%90) The Group primarily relies on internal cash flow and shareholder contributions for operations. As of June 30, 2025, cash and cash equivalents were approximately S$9.6 million, with no bank borrowings. The gearing ratio (total liabilities/total equity) increased from 6% at the end of 2024 to 11%, mainly due to higher lease liabilities. The capital structure is entirely equity-funded Liquidity and Capital Structure Indicators | Indicator | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and Cash Equivalents | 9.6 million S$ | 11 million S$ | | Bank Borrowings | None | None | | Gearing Ratio | 11% | 6% | [Use of Proceeds and Progress on Business Objectives](index=33&type=section&id=%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%85%E7%94%A8%E9%80%94%E8%88%87%E6%A5%AD%E5%8B%99%E7%9B%AE%E6%A8%99%E9%80%B2%E5%B1%95) The net IPO proceeds of S$9.1 million were fully utilized by June 30, 2025. Of the approximately HK$20 million (S$3.6 million) net proceeds from the 2021 placement, S$1.265 million remains unutilized, expected to be used in H2 2025 for acquiring potential businesses and expanding allied health services. The report details the comparison between business objectives in the prospectus and actual progress, showing most plans completed according to the revised allocation - The net IPO proceeds of approximately **S$9.1 million** have been fully utilized[100](index=100&type=chunk)[101](index=101&type=chunk) Placement Proceeds Utilization Summary (As of June 30, 2025) | Purpose | Allocated Amount (S$ '000) | Utilized Amount (S$ '000) | Remaining Amount (S$ '000) | Expected Utilization Time | | :--- | :--- | :--- | :--- | :--- | | Acquisition of Interests in Potential Businesses | 500 | 0 | 500 | H2 2025 | | Allied Health and Ancillary Healthcare Services | 1,000 | 441 | 559 | H2 2025 | | Other Utilized | 2,100 | 2,100 | 0 | - | | **Total** | **3,600** | **2,541** | **1,059** | | [Corporate Governance and Other Information](index=37&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%8F%8A%E5%85%B6%E4%BB%96%E8%B3%87%E6%96%99) The company is committed to maintaining high standards of corporate governance and has complied with most code provisions of the GEM Listing Rules. The sole deviation is the non-separation of the Chairman and Chief Executive Officer roles, both held by founder Dr. Tan Chee Siang, which the Board believes facilitates efficient management. The report discloses that Dr. Tan, as the controlling shareholder, holds a 56.29% interest in the company. No share options were granted, nor were any share repurchases made during the period. The Audit Committee has reviewed this interim report and financial statements - The company has one corporate governance deviation: the roles of Chairman and Chief Executive Officer are not separated, both held by Dr. Tan Chee Siang. The Board believes this arrangement is in the best interest of the Group[107](index=107&type=chunk) - No share options have been granted since the adoption of the share option scheme[110](index=110&type=chunk) - Controlling shareholder Dr. Tan Chee Siang beneficially owns a total of **351,275,000 shares**, representing **56.29%** of the company's issued share capital, through controlled corporations and personally[111](index=111&type=chunk) - The Audit Committee, comprising three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements and this interim report[121](index=121&type=chunk)

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 2025年上半年，面對錯綜複雜的外部環境和諸多壓力挑戰，公司上下凝心聚力、 攻 堅 克 難，牢 牢 把 握 數 智 化 轉 型 重 要 機 遇，緊 扣「一 二 二 五」1戰 略 實 施 思 路，全 面 推 進「三 大 計 劃」2，深 化 改 革 攻 堅、創 新 突 破，深 化 轉 型 升 級、動 能 轉 換，深 化 精 細 運 營、精 益 管 理，經 營 業 績 穩 健 增 長，發 展 質 量 不 斷 提 高，數 智 化 轉 型 取 得 新 成 效，向 世 界 一 流 信 息 服 務 科 技 創 新 公 司 堅 實 邁 進。 2025上半年業績表現 CHINA MOBILE LIMITED 中國移動有限公司 （根據公司條例在香港註冊成立之有限公司） 股份代號：941（港幣櫃台）及 80941（人民幣櫃台） 2025年中期業績 – 1 – • 營運收 ...